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Abstract. Aim: To compare the outcome of 5-fluorouracil
(FU)-based hepatic arterial infusion chemotherapy (HAIC) with
sorafenib monotherapy in patients with hepatocellular
carcinoma (HCC) refractory to transcatheter arterial
chemoembolization (TACE). Patients and Methods: In this
retrospective cohort study, 123 patients with HCC refractory to
TACE, with Child-Pugh A and free of extrahepatic metastasis,
were divided into two groups: 65 received HAIC and 58
received sorafenib. Since the size of main tumor and portal vein
invasion were significantly different between the HAIC and
sorafenib groups, we selected 48 patients from the 65 patients of
the HAIC group and 48 from the 58 patients of the sorafenib
group. The model used one-to-one matching between the two
groups using the case–control method matching method. The
clinical characteristics of patients of the case–control HAIC
(n=48) and sorafenib groups (n=48) were similar. Overall
survival, time to progression and time to treatment failure
(TTTF) were compared between the two groups. Results: The
median survival time and TTTF were significantly longer in the
sorafenib group than in the HAIC group (15 and 12.2 months
versus 8 and 4.4 months, respectively; p=0.021 and p=0.002,
respectively). Multivariate analysis identified male gender
(p=0.008), relative tumor size <50% (p=0.012), α-fetoprotein
<400 ng/ml (p=0.005), and treatment with sorafenib (p=0.001)
as significant and independent determinants of better overall
survival. Conclusion: In patients with HCC refractory to TACE,
overall survival was favorable in those treated with sorafenib
rather than HAIC.
Several studies have reported on clinical benefits of
sorafenib in patients with advanced hepatocellular carcinoma
(HCC), including a placebo-controlled randomized phase III
study (1) and a phase III study performed in the Asia-Pacific
region (2). Sorafenib is currently the only standard therapy in
many countries for patients with advanced HCC and
extrahepatic metastasis, unresectable HCC, refractory to
transcatheter arterial chemoembolization (TACE) and with
macroscopic vascular invasion (MVI). Sorafenib is reported
to prolong overall survival by 2.3-2.8 months and improve
the response rate (RR) by 2.0-3.3%, compared to placebo
(1). Sorafenib also has favorable results in patients with
disease refractory to TACE compared to hepatic arterial
infusion chemotherapy (HAIC) using cisplatin, with a
significantly higher disease control rate, longer time to
progression and increased overall survival (3).
HAIC is widely used in Asia, especially in Japan. The
regimens used in HAIC include cisplatin only, interferon
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plus 5-fluorouracil (5-FU), or cisplatin plus 5-FU. Several
studies have shown the survival benefits of HAIC for
advanced HCC without extrahepatic metastasis, with
response rates ranging from 20.8 to 52% (4-9). The reported
median survival time (MST) in complete and partial
responders is about 40 and 17 months, respectively (4-9). In
the majority of retrospective studies, survival was
significantly better in responders to HAIC than non-
responders (5, 6). In HAIC, the response rate to sorafenib is
usually high and responders have good overall survival (1,
6). However, the response rate and overall survival are poor
in patients with extrahepatic metastasis (10). Furthermore,
the survival of patients with Child-Pugh class B cirrhosis is
significantly inferior to that of patients with Child-Pugh class
A treated with HAIC (9), and the RR and overall survival are
poorer in patients with disease refractory to TACE (11). 
To our knowledge, there are no studies to have compared
the benefits of 5-FU-based-HAIC treatment with sorafenib
monotherapy in patients with HCC refractory to TACE. In
this retrospective cohort study, we compared the response to
HAIC therapy to that of sorafenib monotherapy in patients
with TACE-refractory Child-Pugh A HCC, free from
extrahepatic metastasis.
Patients and Methods
Patients. In this retrospective cohort study, among 325 patients treated
by HAIC and 391 patients treated with sorafenib at our and affiliated
hospitals, we enrolled only 123 patients with HCC, Child-Pugh A
cirrhosis, free from extrahepatic metastasis and refractory to TACE.
We excluded patients who were treated with both HAIC and sorafenib
during the follow-up period. The study included 65 patients who
received HAIC only and 58 who received sorafenib monotherapy. 
Refractoriness to TACE was assessed radiologically on baseline
computed tomography (CT)/magnetic resonance imaging (MRI)
(taken within 3 months of TACE) according to the 2010 JSH
Consensus Guidelines (12), and also by changes in tumor markers
within 2 months of TACE. For the latter, persistent elevation of α-
fetoprotein (AFP) within 2 months after TACE exceeding 20%
relative to the baseline (before TACE) was considered non-response. 
HAIC. HAIC consisted of repeated arterial infusions of anticancer
agents via the injection port. Two drug regimens were used: intra-
arterial low-dose cisplatin combined with 5-FU therapy (FP) and
intra-arterial 5-FU with subcutaneous interferon (IFN) combination
therapy (5-FU+IFN). One course of chemotherapy continued for 2
weeks. 5-FU at 300 mg/kg body weight/day was administered over
24 hours using a mechanical infusion pump from days 1 to 5 of the
first and second weeks in both regimens. Cisplatin was injected
intra-arterially at 6 mg/kg body weight/day on days 1-5 and 8-12.
The IFN used in the 5-FU+IFN regimen was recombinant IFNα-2b
or natural IFN-α, administered intramuscularly on days 1, 3, and 5
of each week (total dose, 36 and 60 MU, respectively). A 2- to 4-
week rest period of no treatment was allowed after each treatment
course (9). A total of 28 patients received FP, while 37 patients
received 5FU+IFN.
Sorafenib monotherapy. Treatment with sorafenib was used between
June 2009 and December 2015, at a dose of 400 mg twice daily.
Treatment interruptions and dose reductions (to 400 mg once daily)
were permitted for adverse drug reactions. Patients continued
sorafenib monotherapy as long as possible, even when disease
progression was noted, until death, or meeting one of the following
criteria for cessation of therapy: adverse events that required
termination of treatment, deterioration of Eastern Cooperative
Oncology Group performance status (ECOG PS) to 4, worsening liver
function, or withdrawal of consent. The criterion for liver function
for treatment discontinuation was a total bilirubin level >3 mg/dl at 4
weeks after cessation of treatment. 
Assessment of response to therapy and safety. The response to
treatment was evaluated by the Response Evaluation Criteria in
Solid Tumors (RECIST) (13) after completion of each course and
at 8 weeks. As part of the assessment, each patient underwent
dynamic CT or MRI every 3-4 months. Overall survival was
assessed from the date of initiation of therapy until the date of death
from any cause. 
Safety was assessed by adverse drug reactions, clinical laboratory
tests, physical examination, and measurement of vital signs. Adverse
drug reactions were defined according to the Common Terminology
Criteria for Adverse Events version 4.0 (14).
Statistical analysis. Continuous variables were expressed as the
mean, while categorical variables were expressed as absolute and
relative frequencies. Univariate analysis was used to investigate the
relationship between overall survival of patients refractory to TACE
after initiation of therapy and various clinicopathological variables.
Overall survival was studied by Kaplan–Meier survival curves with
log-rank survival comparisons and 95% confidence interval (CI). A
Cox proportional hazards model was used to identify the prognostic
factors for overall survival. 
Since the size of the main tumor, portal vain invasion (Vp) and
des-γ-carboxy prothrombin (DCP) were significantly different
between the HAIC and sorafenib groups (see Results), we selected
48 patients from the 65 patients of the HAIC group and 48 from the
58 patients of the sorafenib group. The model used one-to-one
matching between the two groups by using the case–control
matching method (15). 
A p-value less than 0.05 denoted the presence of a statistically
significant difference. All statistical analyses were carried out with the
Predictive Analytics Software v21.0 (IBM Corp., Armonk, NY, USA).
Results 
Patients’ clinical characteristics. Table I lists the
differences between patients of the HAIC-treated and
sorafenib-treated groups. Since the size of main tumor and
Vp were significantly different between the two groups,
we selected 48 patients from the 65 patients of the HAIC-
treated group and 48 from the 58 patients of the sorafenib-
treated group (Figure 1). The model used one-to-one match
between the two groups by using the case–control method
matching method. Table II shows that the clinical
characteristics of patients of the case–control HAIC (n=48)
and sorafenib groups (n=48) were similar. These patients
ANTICANCER RESEARCH 36: 3523-3530 (2016)
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met the study eligibility criteria and were matched for age,
gender, etiology, platelet count, tumor size, Vp, TNM
stage, Barcelona Clinic Liver Cancer Staging classification
(BCLC), AFP, and DCP. 
Response to therapy. The proportions of patients with
complete response (CR), partial response (PR), stable disease
(SD), and progressive disease (PD) were 0%,12%, 54% and
27% for the HAIC group, and 2%, 4%, 60%. and 27% for
the sorafenib group. The response rate was similar for the
HAIC and sorafenib groups (12% and 6%, p=0.4). 
The median survival time was better in the sorafenib
group (months) than the HAIC group (15 versus 8 months,
p=0.021; Figure 2a). The time to progression was also
similar (2.8 months versus 4.0 months, respectively, p=0.5;
Figure 2b). The time to treatment failure was longer in the
sorafenib group (12.2 versus 4.4 months,  respectively,
p=0.001; Figure 2c). For the MST of patients treated with
Hatooka et al: Sorafenib Treatment for Chemoembolization Failure
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Table I. Characteristics of patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
Characteristic HAIC (n=65) Sorafenib (n=58) p-Value
Age (range), years 67 (46-84) 70 (50-88) 0.08
Gender (male/female) 59/6 43/15 0.05
PS (0/1) 63/2 54/4 1.0
HBV/HCV/NBNC 15/43/7 13/40/5 0.8
Platelet count (range), ×104/μl 12.2 (4.6-88.8) 15.3 (5.3-20.7) 0.4
Size of main tumor (range), mm 40 (15-140) 32 (5-190) 0.017
Relative tumor size (<50%/≥50%) 52/13 40/18 0.4
Vp (0-2/3-4) 42/23 52/6 0.001
No. of tumors (solitary/multiple) 17/48 24/34 0.1
TMN stage II/III/IVa 4/27/34 10/42/6 0.001
BCLC (B/C) 42/23 52/6 0.001
AFP (range), ng/ml 415.3 (5-191500) 449 (5-2446) 0.2
DCP (range), mAU/ml 370 (7-16163) 414 (14-58970) 0.06
No. of prior TACE sessions (range) 4 (2-9) 3 (2-8) 0.1
PS: Perfomance status, HBV: hepatitis B viral infection, HCV: hepatitis C viral infection, NBNC: non-B-non-C viral hepatitis, Vp: portal vain
invasion, TMN: TMN Classification of Malignant Tumors, BCLC: Barcelona Clinic Liver Cancer Staging classification, AFP: α-fetoprotein, DCP:
des-γ-carboxy prothrombin. Data are median values.
Table II. Characteristics of patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization for the case–control
method.
Characteristic HAIC (n=48) Sorafenib (n=48) p-Value
Age (range), years 68 (46-83) 68 (50-88) 0.5
Gender male/female, n 42/6 36/12 0.19
PS 0/1, n 46/2 45/3 0.55
HBV/HCV/NBNC, n 11/32/5 12/33/3 1.0
Platelet count (range), ×104/μl 12.2 (4.6-88.8) 15.3 (5.3-20.7) 0.4
Size of main tumor (range), mm 38 (15-140) 33 (10-80) 0.23
Relative tumor size, (<50%/≥50%) ,n 40/8 37/11 1.0
Vp, 0-2/3-4, n 42/6 42/6 1.0
No. of tumors, solitary/multiple 9/39 9/39 1.0
TMN stage II/III/IVa, n 2/40/6 2/40/6 1.0
BCLC, B/C, n 42/6 42/6 1.0
AFP (range), ng/ml 415.3 (5-191500) 305 (5-12230) 0.5
DCP (range), mAU/ml 338 (7-13044) 412 (14-9300) 0.5
No. of prior TACE sessions (range) 4 (2-9) 3 (2-8) 0.1
HAIC: Hepatic arterial infusion chemotherapy, PS: perfomance status, HBV: hepatitis B viral infection, HCV: hepatitis C viral infection, NBNC: non-
B-non-C viral hepatitis, Vp: portal vain invasion , TMN: TMN Classification of Malignant Tumors, BCLC: Barcelona Clinic Liver Cancer Staging
classification, AFP: α-fetoprotein, DCP: des-γ-carboxy prothrombin. Data are median values.
HAIC, there was no significant difference between those
treated with FP and those treated with 5-FU+IFN.
The MST was longer in patients of the sorafenib group
with CR (n=1). The MST of the patients with PR in the
sorafenib (n=2) and HAIC (n=6) groups was 33 and 19
months, respectively (p=0.1); while for those with SD, the
MST was 18 (n=29) and 12 (n=26) months, respectively
(p=0.3). Furthermore, the MST of the patients with PD was
9 (n=13) and 3 (n=13) months, respectively (p=0.001). 
Determinants of overall survival. Overall survival
correlated significantly with gender (p=0.012), relative
tumor size (p=0.049), Vp (p=0.0001), AFP (p=0.005) and
treatment type (p=0.001). Multivariate analysis identified
male gender (p=0.008) relative tumor size <50%
(p=0.012), AFP <400 ng/ml (p=0.005), and treatment with
sorafenib (p=0.001) as significant and independent
determinants of better overall survival (Table III).
Overall survival according to MVI. In the HAIC group, the
MST was not different between Vp0-2 (9 months) and Vp3-
4 (7 month; p=0.5, Figure 3a), nor did it differ in the
sorafenib group (12 versus 19 months, respectively, p=0.3;
Figure 3b).
Adverse events. In the HAIC group, CTCAE grade 3/4 liver
failure occurred in two patients (4.0%), hypersensitivity
reaction to cisplatin in one patient (2.0%) and infection of the
injection port in one (2.2%). In the sorafenib group, CTCAE
grade 3/4 worsening of PS occurred in one patient (2.2%) and
diarrhea and general fatigue in one patient (2.2%). 
Discussion
Sorafenib is standard treatment for HCC refractory to TACE
(16). The appearance of extrahepatic metastasis, MVI and
enlargement of hepatic tumor are examples of lack of
response to TACE. In this study, we selected patients with
Child-Pugh A who were free of extrahepatic metastases and
refractory to TACE. We also excluded patients who were
treated with both HAIC and sorafenib during the follow-up
period. In such patients, a switch to sorafenib is
recommended rather than continuation of TACE (17).
Another study reported that sorafenib is better than HAIC
using cisplatin for HCC refractory to TACE (3). To our
knowledge, however, there are no studies that compared
sorafenib with HAIC using 5-FU for patients who failed
se.to respond to TACE. For the above reasons, the present
study was designed to compare the response to 5-FU-based
HAIC and sorafenib in HCC refractory to TACE in patients
with Child-Pugh A cirrhosis, free from extrahepatic
metastasis.
Strict comparisons with previous studies is sometimes
difficult since such studies included patients whose disease
was not refractory to TACE and the patient selection
process allowed potential biases. For example, in the study
of Ikeda et al., 33% and 45% of patients treated with
sorafenib and HAIC, respectively, had Child-Pugh B
cirrhosis (3). This is important, since Child-Pugh B
cirrhosis is a well-known poor prognostic factor in patients
treated with sorafenib. Another limitation of the above
study was inclusion of eight out of 66 (12%) patients who
were switched from HAIC to sorafenib.
ANTICANCER RESEARCH 36: 3523-3530 (2016)
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Figure 1. Flow-chart of patient recruitment.
Our results showed that sorafenib provided a better MST
(15 months) than HAIC (8 months). The first reason for this
is that the time to treatment failure of sorafenib is longer
than HAIC: patients who received sorafenib were treated for
a longer period than those treated with HAIC. The second
reason is the need to withdraw treatment due to stenosis of
the hepatic artery by catheter therapy, reduced sensitivity to
the drug, deterioration of liver function, or the appearance of
collateral arteries. 
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Figure 2. Overall survival (a), time to progression (b), and time to
treatment failure (c) for hepatic arterial infusion chemotherapy (HAIC)
and sorafenib in patients with hepatocellular carcinoma. 
Figure 3. Overall survival after hepatic arterial infusion chemotherapy
(HAIC) (a) and sorafenib (b) therapy of hepatocellular carcinoma
according to portal vain invasion (Vp). Vp 0, No tumor thrombus; Vp,
one tumor thrombus in the second branch of the portal vein; Vp 3,
tumor thrombus in the first branch of the portal vein; Vp 4, tumor
thrombus in the trunk of the portal vein. 
In both groups, the MST was not significantly different
between Vp0-2 and Vp3-4. Generally, among patients with
MVI, it has been reported that HAIC provides more
favorable survival than sorafenib (18). However, in the
present study, in which the subject was TACE-refractory
patients, the superiority of HAIC to sorafenib was not
demonstrated among patients with MVI. This might be due
to stenosis of the hepatic artery by catheter therapy, or
reduced sensitivity to the drug. 
Our study has certain limitations. Firstly, the study included
only a small number of patients and was retrospective in nature.
However, we selected patients with Child-Pugh A cirrhosis who
were free of extrahepatic metastasis and refractory to TACE.
We also excluded patients who were treated with both HAIC
and sorafenib during the follow-up period, thus allowing us to
study selected groups of patients. We believe that the present
study provides important information on the management of
patients with HCC refractory to TACE.
In conclusion, sorafenib led to favorable overall survival
among HCC patients refractory to TACE compared to those
treated with HAIC. Further large-scale prospective studies
are needed to compare the effects of HAIC with sorafenib.
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Table III. Results of univariate and multivariate analyses for prognostic factors in patients with hepatocellular carcinoma refractory to transcatheter
arterial chemoembolization.
Univariate Multivariate
N Median (months) HR 95% CI p-Value HR 95% CI p-Value
Age (years)
<67 48 13 0.6 0.4-1.03 0.069
≥67 48 10 1.0
Gender 
Male 78 12.2 0.4 0.20.8 0.012 0.23 0.2-0.8 0.008
Female 18 8 1.0
Etiology 
HCV 65 11.3 1.0 0.3-1.3 0.2
Other 23 8.9 1.0
Platelet count (×104/μl) 
<15 48 11.3 1.0 0.3-1.3 0.2
≥15 48 8.9 1.0
Size of main tumor (mm)  
≥38 48 8.9 1.4 1.03-2.5 0.035
<38 48 16 1.0
Relative tumor size 
≥50% 68 6 1.6 0.9-3.0 0.049 2.2 1.1-4.3 0.012
<50% 18 13 1.0
Vp
3-4 12 3 3.7 1.8-7.7 0.0001 4.4 1.9-9.9 0.0001
0-2 84 12 1.0
No. of tumors
Multiple 78 10 0.3 0.04-2.5 0.2
Solitary 18 19 1.0
AFP (ng/ml) 
≥400 48 7 1.7 1.1-2.8 0.01 2.1 1.2-3.6 0.005
<400 48 16 1.0
DCP (mAU/ml) 
≥400 48 10.2 0.2 0.3-1.1 1.3
<400 48 11.3 1.0
Treatment 
Sorafenib 48 15 0.4 0.2-0.8 0.007 0.3 0.2-0.6 0.001
HAIC 48 8 1.0
HR: Hazard ratio, CI: confidence interval, PS: perfomance status, HBV: hepatitis B viral infection, HCV: hepatitis C viral infection, NBNC: non-
B-non-C viral hepatitis, Vp: portal vain invasion, TMN: TMN Classification of Malignant Tumors, BCLC: Barcelona Clinic Liver Cancer Staging
classification, AFP: α-fetoprotein, DCP: des-γ-carboxy prothrombin.
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